EUCTR2020-004930-39-ES进行中（未招募）1 期
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Female or male patients with evaluable locally advanced unresectable or metastatic TNBC
- •2. Age >/=18 years
- •3. Histological or cytological confirmation of hormone (estrogen and progesterone) receptor negative tumor by immunohistochemistry (IHC) assessment (defined as <1% nuclei staining) and HER2-negative, non-overexpressing (by IHC [0 or 1+] OR in situ hybridization [ratio <2.0] OR average HER2 gene copy number of <4 signals/nucleus) per 2018 American Society of Clinical Oncology and the College of American Pathologists (ASCO CAP) criteria.
- •4. Prior systemic therapies (Cohort 1):
- •a. No prior systemic therapy in the locally advanced unresectable/metastatic setting including chemotherapy, targeted therapy, immunotherapy, or investigational agents.
- •b. Prior PD-1/PD-L1 inhibitor treatment is not permitted in any setting, including in the neoadjuvant setting.
- •c. Time between completion of last treatment with curative intent and first metastatic recurrence must be >/= 6 months.
- •d. Only patients for whom treatment with a PD-1/PD-L1 inhibitor is not an option, either based on clinical eligibility or drug availability, will be enrolled in Cohort 1.
- •5. Prior systemic therapies (Cohort 2):
- •a. Documentation of PD-L1 positive status
- •b. Treated with a PD-1/PD L1 inhibitor for a minimum duration of 4 months in the locally advanced unresectable/metastatic setting and as the most recent therapy. Washout of at least 14 days from prior PD-1/PD L1 inhibitor to the first dose of study drug is required.
- •6. Radiation therapy for metastatic disease is permitted. There is no required minimum washout period for these therapies. Patients should be recovered from the effects of radiation.
- •7. Archival tumor tissue must be available or a fresh biopsy must be obtained, unless approved by the Medical Monitor. If archival tissue is used, representative formalin-fixed paraffin embedded (FFPE) tumor specimens in paraffin blocks (75-micron) or at least 15 (5-micron) unstained slides are required.
- •a. For Cohort 1 only, some of the tumor tissue noted above will be used for determination of tumor PD-L1 status using the Ventana SP-142 IVD assay which can be assay locally or centrally. Testing should be conducted on a recurrent/metastatic tumor; however, a primary lesion is acceptable. Documentation of PD-L1 status is acceptable for randomization if testing was done using the Ventana SP-142 IVD assay.
- •8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •9. Adequate organ function as demonstrated by:
- •a. Hemoglobin >/=9.0 g/dL in the absence of RBC transfusion or ESA administration within 14 days prior to first dose of study drug
- •b. Absolute neutrophil count (ANC) >/=1.5 × 109/L
- •c. Platelet count >/=100 × 109/L
- •d. Estimated glomerular filtration rate >/=30 mL/minute/1.73 m2
- •e. Total bilirubin f. ALT and AST 10. Resolution of nonhematologic toxicities from prior systemic therapy, radiation therapy, or surgical procedures to 11. Predicted life expectancy of =3 months
- •12. Contraceptive use by men or women should be consistent with respective local regulations for those participating in clinical studies. Please see Section 17.3 for detailed required instructions
- •13. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed con
排除标准
- •A patient will not be eligible for participation in this study if any of the following criteria apply:
- •1. Prior treatment with gemcitabine in any setting.
- •2. Prior treatment with carboplatin in the locally advanced unresectable/metastatic setting. Prior carboplatin in the (neo)adjuvant/curative setting is permitted as long as it was completed >/= 6 months prior to the first metastatic recurrence
- •3. Malignancies other than TNBC within 3 years prior to randomization: Patients with malignancies of a negligible risk of metastasis or death (e.g., risk of metastasis or death <5% at 5 years as determined by the investigator) are eligible provided they meet all of the following criteria:
- •a. Malignancy treated with expected curative intent (e.g., adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent)
- •b. No evidence of recurrence or metastasis by follow-up imaging and any disease-specific tumor markers
- •4. Presence of central nervous system (CNS) metastases and/or leptomeningeal disease requiring immediate treatment with radiation therapy or steroids. Patient must be off steroids administered for brain metastases for at least 14 days prior to the first dose of study drugs. No stereotactic radiation within 7 days or whole-brain radiation within 14 days prior to first dose of study drugs
- •5. Receipt of any cytotoxic chemotherapy within 14 days prior to the first dose of study drugs
- •6. Receipt of any investigational medication within 30 days, or at least 5 half-lives, whichever is greater, prior to the first dose of study drugs
- •7. QTcF interval >480 msec at Screening. For patients with ventricular pacemakers, QTcF >500 msec
- •8. Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure (Class III or IV as defined by the New York Heart Association [NYHA] functional classification system)
- •9. Known history of stroke or cerebrovascular accident within 6 months prior to first dose of study drugs
- •10. Known serious active infection (e.g., human immunodeficiency virus [HIV], hepatitis B or C, tuberculosis). Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
- •11. Known hypersensitivity to carboplatin or other platinum-containing compounds, or mannitol
- •12. Pregnant or lactating women
- •13. Prior hematopoietic stem cell or bone marrow transplantation
- •14. Other uncontrolled serious chronic disease or psychiatric condition that in the Investigator’s opinion could affect patient safety, compliance, or follow-up in the protocol
- •15. Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to first dose of study drugs, or anticipation of the need for major surgical procedure during the course of the study
- •16. Receipt of a live, attenuated vaccine within 30 days prior to the first dose of study drugs or anticipation that such a live, attenuated vaccine will be required during the study treatment period
研究者
相似试验
进行中（未招募）
1 期
eoadjuvant chemotherapy with Atezolizumab or Placebo followed by adjuvant Atezolizumab or PlaceboPatients with early breast cancerMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002771-25-DESABP Foundation Inc.1,550
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo GeparDouzePatients with early breast cancerMedDRA version: 20.0Level: LLTClassification code: 10007050Term: Cancer Class: 10029104CTIS2023-508472-11-00SABP Foundation Inc.1,550
进行中（未招募）
1 期
eoadjuvant chemotherapy with Atezolizumab or Placebo followed by adjuvant Atezolizumab or PlaceboPatients with early breast cancerMedDRA version: 20.0 Level: LLT Classification code 10007050 Term: Cancer System Organ Class: 100000004864EUCTR2017-002771-25-ESSABP Foundation Inc.1,520
尚未招募
3 期
CV638 ability to protect against homologous Vibrio cholerae 3008 virulent straicholera infectionVibrio InfectionsGram-Negative Bacterial InfectionsBacterial InfectionsWaterborne DiseasesEnvironmental IllnessCholeraRPCEC00000228Finlay Institute of Vaccines (IFV)120
进行中（未招募）
1 期
A clinical trial to determine whether tivantinib is safe and effective in the treatment of liver cancerMET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC)MedDRA version: 14.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864EUCTR2012-003308-10-ITDAIICHI SANKIO DEVELOPMENT LIMITED303